文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

静脉-动脉体外膜氧合支持期间大出血的临床相关因素:时间依赖性视角

Clinical correlates for major bleeding during veno-arterial extracorporeal membrane oxygenation support: a time-dependent perspective.
PubMed 文献 · Crit Care · 2026-03-26
一句话结论VA ECMO患者中42%发生大出血,多早期出现,出血前凝血和炎症标志物呈动态变化,出血与ICU死亡率升高相关(HR 1.39)。

该前瞻性队列纳入2016-2023年6家荷兰中心558例因心力衰竭接受VA ECMO的成人,大出血定义为需外科或放射介入和/或24小时内输注>3单位红细胞。232例(42%)发生至少1次大出血,共342次事件(发生率112/1000风险日),56%发生在48小时内(插管部位37%、胸腔内38%),48小时后事件以胸腔内为主(53%)。出血前可见活化部分凝血活酶时间、凝血酶原时间、肝素比值、抗Xa因子和国际标准化比值升高,血小板计数、血红蛋白和白细胞降低;女性性别和较低体重与出血相关(均p<0.01)。出血与更高的ICU死亡率相关(HR 1.39,95%CI 1.09-1.76,p<0.01)。

要点

  • 558例VA ECMO成人中232例(42%)发生至少1次大出血,共342次事件,发生率112/1000风险日。
  • 大出血多发生在早期(<48小时,n=190,56%),以插管部位(37%)和胸腔内(38%)为主。
  • 48小时后出血事件(n=152,44%)以胸腔内为主(53%)。
  • 出血前活化部分凝血活酶时间、凝血酶原时间、肝素比值、抗Xa因子和国际标准化比值升高,血小板计数、血红蛋白和白细胞降低。
  • 女性性别和较低体重与出血相关(均p<0.01);出血与ICU死亡率升高相关(HR 1.39,95%CI 1.09-1.76,p<0.01)。

适用人群与场景

  • 2016-2023年6家荷兰中心因心力衰竭接受VA ECMO的所有成人。

诊断标准与关键阈值

  • 大出血定义:需要外科或放射介入和/或24小时内输注>3单位红细胞。

研究设计与关键结果

  • 前瞻性队列纳入558例VA ECMO支持患者,232例(42%)发生至少1次大出血,共342次事件(发生率112/1000风险日)。
  • 早期出血(<48小时)n=190(56%),主要位于插管部位(37%)和胸腔内(38%);晚期出血(>48小时)n=152(44%),以胸腔内为主(53%)。
  • 女性性别和较低体重与出血相关(均p<0.01)。
  • 与匹配对照相比,出血患者出血前活化部分凝血活酶时间、凝血酶原时间、肝素比值、抗Xa因子和国际标准化比值升高,血小板计数、血红蛋白和白细胞降低。
  • 出血与更高的ICU死亡率相关(HR 1.39,95%CI 1.09-1.76,p<0.01)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,出血患者与未出血患者凝血和炎症标志物的轨迹差异凸显了VA ECMO期间出血风险的动态性质,并为动态出血风险预测提供了未来机会。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Major bleeding is a common and serious complication of veno-arterial extracorporeal membrane oxygenation (VA ECMO). Current perspectives on bleeding risk fail to reflect dynamic changes over time in bleeding incidence and risk factors for bleeding.

METHODS: All adults receiving VA ECMO (2016-2023) for cardiac failure in 6 participating Dutch centers were included in a prospective cohort. Major bleeding was defined as bleeding requiring surgical or radiological intervention and/or transfusion of > 3 red blood cell units within 24 h. Bleeding cases were matched up to 4 controls who had not (yet) bled at that timepoint. Generalized additive models were applied to visualize trajectories of coagulation, inflammatory, and perfusion markers, exploring temporal differences between bleeding cases and matched controls.

RESULTS: Among 558 VA ECMO supported patients, 232 (42%) experienced ≥ 1 major bleeding event, totaling 342 episodes (incidence rate 112 per 1000 days at risk). Most bleeding events occurred early (< 48 h; n = 190, 56%), primarily at the cannulation site (37%) and intrathoracically (38%). Fewer events occurred later (> 48 h; n = 152, 44%), predominantly intrathoracically (53%). Female sex and lower body weight (both p < 0.01) were associated with bleeding. Compared with controls, patients who developed bleeding showed increased activated partial thromboplastin time, prothrombin time, heparin ratio, anti-factor Xa and international normalized ratio preceding bleeding, whereas platelet count, hemoglobin and leukocytes were lower. Bleeding was associated with higher intensive care mortality (HR 1.39, 95% CI 1.09-1.76, p < 0.01).

CONCLUSION: A severe major bleeding developed in nearly half of all patients and was associated with an increased mortality risk. The trajectories of coagulation and inflammatory markers observed in patients with versus without bleeding events underscore the dynamic nature of bleeding risk and highlight future opportunities for dynamic bleeding risk prediction during VA ECMO.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Pladet LCA, Boubrik H, Luijken K, et al. Clinical correlates for major bleeding during veno-arterial extracorporeal membrane oxygenation support: a time-dependent perspective. Crit Care. 2026. PMID: 41888853. doi:10.1186/s13054-026-05856-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。